Celliaz

Celliaz is a South Korean biotechnology company founded in 2022 as a faculty startup from the Korea Advanced Institute of Science and Technology (KAIST). The company is pioneering a first-in-class retinal regeneration platform based on PROX1 modulation, which reactivates the retina's endogenous regenerative potential to restore vision rather than merely slowing disease progression. Celliaz's pipeline includes CLZ001, an intravitreal antibody protein therapy for wet age-related macular degeneration (wet-AMD), and CLZ002, an adeno-associated virus (AAV)-based gene therapy for retinitis pigmentosa (RP). By blocking the intercellular transfer of PROX1, a protein that acts as a brake on retinal regeneration, Celliaz aims to restore the regenerative capacity of Müller glia cells. The company is currently advancing its candidates through preclinical development and preparing for clinical trials.